GDUFA II January-March Report

[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]

According to the FY 2018, GDUFA II quarterly performance report covering January through March 2018 the number of ANDAs awaiting FDA action (1930) declined by 8% in the second quarter from the previous quarter (2055). Mean full approval and tenta- tive approval times declined by greater than 20%.

[/membership]